title: Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside.
abstract: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common treatable chronic autoimmune neuropathy. Multiple diagnostic criteria have been established, with the primary goal of identifying neurophysiologic hallmarks of acquired demyelination. Treatment modalities have expanded to include numerous immunomodulatory therapies, although the best evidence continues to be for corticosteroids, plasma exchange, and intravenous immunoglobulin (IVIg). This review describes the pathology, epidemiology, pathogenesis, diagnosis, and treatment of CIDP.
authors.affiliation: Department of Neurology, Vanderbilt Medical Center, Medical Center North, Nashville, Tennessee 37232-2551, USA. amanda_c_peltier@vanderbilt.edu
authors.forename: Amanda C
authors.initials: AC
authors.lastname: Peltier
authors.forename: Peter D
authors.initials: PD
authors.lastname: Donofrio
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000418:Albumins / Q000378:metabolism; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D004568:Electrodiagnosis; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010525:Peripheral Nerves / Q000473:pathology; D010951:Plasma Exchange; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000134:cerebrospinal fluid / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D033581:Stem Cell Transplantation
chemical_list: D000305:Adrenal Cortex Hormones; D000418:Albumins; D000893:Anti-Inflammatory Agents; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents